Total blood eosinophils, serum eosinophil cationic protein and eosinophil protein X in childhood asthma: Relation to disease status and therapy

Zimmerman, B.; Lanner, A.; Enander, I.; Zimmerman, R.S.; Peterson, C.G.; Ahlstedt, S.

Clinical and Experimental Allergy Journal of the British Society for Allergy and Clinical Immunology 23(7): 564-570

1993


ISSN/ISBN: 0954-7894
PMID: 8221257
DOI: 10.1111/j.1365-2222.1993.tb00895.x
Accession: 009655586

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Blood eosinophils, and serum levels of the eosinophil proteins, eosinophil cationic protein (ECP) and eosinophil protein X (EPX) were measured in childhood asthma. Seventeen patients mean age 11.9 years who were symptomatic with asthma, were enrolled in a study examining the eosinophil counts and eosinophil proteins at the onset of study and after treatment in relation to changes in their baseline forced expiratory volume at 1 second (FEV-1) and %predicted FEV-1. The patients with symptomatic asthma were compared with 17 patients mean age 12.0 years with asymptomatic asthma maintained on daily inhaled steroid and 13 patients, mean age 12.0 years, without asthma but with urticaria who served as non-asthma controls. Patients with symptomatic asthma did not have significantly higher initial eosinophil counts compared with those with asymptomatic asthma (0.43 times 10-9/l vs 0.26 times 10-9/l, P=0.09) but had higher serum ECP levels (28.9 mu-g/l vs 18.5 mu-g/l). Both asthma patient groups had significantly higher serum ECP levels (P lt 0.01) than the controls (9.8 mu-g/l). After therapy consisting of increased dose of inhaled steroids and/or oral steroids, patients in the symptomatic asthma group demonstrated a significant rise in FEV-1 (1.67 l/sec at Visit 1 vs 2.08 l/sec at Visit 2, P lt 0.001). A similar rise was seen for %predicted FEV-1. Patients in the asymptomatic asthma group showed no significant change in FEV-1 between visits (2.23 l/sec vs 2.37 l/sec), which was verified with the %predicted FEV-1. Patients in the symptomatic asthma group showed a significant decrease in ECP level following treatment (28.9 mu-g/l to 9.6 mu-g/l, P lt 0.001) while the values in the asymptomatic group did not change (18.6 mu-g/l to 15.2 mu-g/l not significant). There was a significant correlation between the initial ECP level in the symptomatic asthma group and the change in the FEV-1 with treatment. Serum EPX levels showed similar trends but there was no significant correlation between the initial EPX levels and the changes in FEV-1. Neither did blood eosinophil counts show such a correlation. This data suggests that the changes in serum ECP levels correlate with the changes in lung function subsequently to antiinflammation therapy.

Total blood eosinophils, serum eosinophil cationic protein and eosinophil protein X in childhood asthma: Relation to disease status and therapy